Here, we screen the effects of front-line NSCLC chemotherapeutic agents on PD-L1 expression in NSCLC cell lines and activation of tumor-infiltrating T-lymphocytes (TILs) in combination with ICB therapy. Here, CD274 is linked to neoplasm.